ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary […]
Equities research analysts predict that ChromaDex Co. (NASDAQ:CDXC – Get Rating) will announce ($0.09) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for ChromaDex’s earnings, with estimates ranging from ($0.12) to ($0.06). ChromaDex posted earnings of ($0.12) per share in the same quarter last year, which indicates […]